newsfilter
← Latest News
GlobeNewswire·

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

TOVX
  • Theriva Biologics (NYSE: TOVX) entered a warrant inducement agreement with existing institutional investors to exercise up to 7,360,460 existing warrants at a reduced price of $0.54 per share.
  • The transaction aims to generate approximately $4.0 million in gross cash proceeds, with the offer open until 11:30 AM ET for an additional $0.4 million.
  • Investors exercising the existing warrants will receive new unregistered warrants in a private placement, totaling up to 14,720,920 shares.
  • The new warrants carry an exercise price of $0.54 per share, become exercisable upon stockholder approval, and expire five years after that approval date.
  • Theriva intends to use the net proceeds for working capital and general corporate purposes.
  • The closing of the transaction is expected on or about October 17, 2025, subject to customary closing conditions.
  • A.G.P./Alliance Global Partners served as the exclusive financial advisor for the transaction.
  • The securities were offered only to accredited investors under an exemption from registration requirements, with a commitment to file a registration statement for resale.
  • Theriva is a clinical-stage company developing therapeutics for cancer, including lead candidates VCN-01, SYN-004, and SYN-020.